Korro Bio Appoints Dr. Rachel Meyers to Board of Directors
28 November 2023 - 2:00PM
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company
focused on developing a new class of genetic medicines for both
rare and highly prevalent diseases using its proprietary RNA
editing platform, today announced the appointment of Rachel Meyers,
PhD, to the Company’s Board of Directors.
“Rachel is one of the pioneers in advancing LNP
and conjugate-based oligonucleotide therapies to the clinic and
generating regulatory approvals,” said Ram Aiyar, PhD, Chief
Executive Officer of Korro. "With over two decades of research,
development and leadership experience in RNA-based medicines,
Rachel’s insights and perspectives will further strengthen our
ability to leverage our RNA editing platform. We are excited to
welcome her to the Board and look forward to working closely with
her as we advance our lead product towards the clinic."
Dr. Meyers is a seasoned biotechnology veteran
whose experience in life sciences spans over two decades. Most
recently, Dr. Meyers served as Chief Scientific Officer of Faze
Medicines. Previously, she was an Entrepreneur-in-Residence at
Third Rock Ventures. Before that, Dr. Meyers held multiple
leadership positions at Alnylam Pharmaceuticals for over 13 years,
most recently as Senior Vice President of Research and RNAi Lead
Development.
Rachel completed her post-doctoral training at
Harvard University and holds a PhD in Biology from the
Massachusetts Institute of Technology and a BA in Biochemistry from
Brandeis University.
“I've always held a strong conviction in the
transformative potential of RNA for pioneering therapies that
target the root causes of diseases. Joining the Board of Directors
of Korro, a company leading the way in advancing this field, is
very exciting,” said Dr. Meyers. “I am impressed with Korro’s
technology and leadership team, and I look forward to working with
them to execute on the company’s goal to radically transform the
treatment paradigm for both rare and prevalent diseases.”
About Korro
Korro is a biopharmaceutical company focused on
developing a new class of genetic medicines for both rare and
highly prevalent diseases using its proprietary RNA editing
platform. Korro is generating a portfolio of differentiated
programs that are designed to harness the body’s natural RNA
editing process to effect a precise yet transient single base edit.
By editing RNA instead of DNA, Korro is expanding the reach of
genetic medicines by delivering additional precision and
tunability, which has the potential for increased specificity and
improved long-term tolerability. Using an oligonucleotide-based
approach, Korro expects to bring its medicines to patients by
leveraging its proprietary platform with precedented delivery
modalities, manufacturing know-how, and established regulatory
pathways of approved oligonucleotide drugs. Korro is based in
Cambridge, Mass. For more information,
visit korrobio.com.
Korro Contact Information
InvestorsIR@korrobio.com
MediaGlenn SilverFINN PartnersGlenn.silver@finnpartners.com
Korro Bio (NASDAQ:KRRO)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Korro Bio (NASDAQ:KRRO)
Historical Stock Chart
Von Jun 2023 bis Jun 2024